HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Melamine In U.S. Could Pose More Risk To Food Safety Regime Than Infants

This article was originally published in The Tan Sheet

Executive Summary

FDA says trace amounts of melamine found in U.S.-manufactured infant formula poses no danger, but the discovery will likely lead to a renewed push for food safety oversight and possibly for a separate food safety agency

You may also be interested in...



Finished Product Manufacturers Top FDA’s GMP Inspection Targets

Finished product manufacturers are FDA's "first priority" for dietary supplement good manufacturing practice inspections, with contract manufacturers a close second, according to an agency official.

China Takes "Baby Steps" Toward More Open Supplement Regulation

China's health product regulators are taking "baby steps" toward more streamlined approval of supplements, but multi-ingredient products likely will face a series of hurdles before market, says Jeff Crowther, former executive director of the Natural Products Association's Beijing office

Recall Strategy Crucial As Broader Awareness Leaves Firms Vulnerable

As consumer awareness and media attention to food and drug recalls grow, so does the threat recalls pose to firms' bottom lines and the need for companies to build their reputations before problems happen and communicate effectively with the public

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS137065

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel